Invention Grant
US08642041B2 Adenylyl cyclase-associated protein (CAP1) and uses thereof as a target for immuno-modulation
有权
腺苷酸环化酶相关蛋白（CAP1）及其用作免疫调节的靶标
- Patent Title: Adenylyl cyclase-associated protein (CAP1) and uses thereof as a target for immuno-modulation
- Patent Title (中): 腺苷酸环化酶相关蛋白（CAP1）及其用作免疫调节的靶标
-
Application No.: US13257633Application Date: 2010-03-21
-
Publication No.: US08642041B2Publication Date: 2014-02-04
- Inventor: Yaakov Naparstek , Eli Moallem
- Applicant: Yaakov Naparstek , Eli Moallem
- Applicant Address: IL Jerusalem
- Assignee: Protab Ltd.
- Current Assignee: Protab Ltd.
- Current Assignee Address: IL Jerusalem
- Agency: Browdy and Neimark, PLLC
- International Application: PCT/IL2010/000231 WO 20100321
- International Announcement: WO2010/113148 WO 20101007
- Main IPC: A61K39/00
- IPC: A61K39/00
Abstract:
The present invention relates to the use of Adenylyl Cyclase-Associated Protein (CAP1) as a target for immuno-modulation. More specifically, the invention relates to the use of compounds that interact and bind CAP1, specifically, anti-CAP1 antibodies, and/or to CAP1 molecule or any fragments thereof, for the treatment of immune-related disorders by modulation of the Th1/Th2 balance. The invention further provides screening method for immuno-modulatory compounds that interact with CAP1.
Public/Granted literature
- US20120014973A1 ADENYLYL CYCLASE-ASSOCIATED PROTEIN (CAP1) AND USES THEREOF AS A TARGET FOR IMMUNO-MODULATION Public/Granted day:2012-01-19
Information query
